Terns Pharmaceuticals (TERN) Income from Continuing Operations: 2020-2024
Historic Income from Continuing Operations for Terns Pharmaceuticals (TERN) over the last 5 years, with Dec 2024 value amounting to -$89.6 million.
- Terns Pharmaceuticals' Income from Continuing Operations fell 31.27% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 49.01%. This contributed to the annual value of -$89.6 million for FY2024, which is 0.79% up from last year.
- According to the latest figures from FY2024, Terns Pharmaceuticals' Income from Continuing Operations is -$89.6 million, which was up 0.79% from -$90.3 million recorded in FY2023.
- In the past 5 years, Terns Pharmaceuticals' Income from Continuing Operations registered a high of -$41.8 million during FY2020, and its lowest value of -$90.3 million during FY2023.
- Its 3-year average for Income from Continuing Operations is -$80.1 million, with a median of -$89.6 million in 2024.
- In the last 5 years, Terns Pharmaceuticals' Income from Continuing Operations tumbled by 49.01% in 2023 and then grew by 0.79% in 2024.
- Yearly analysis of 5 years shows Terns Pharmaceuticals' Income from Continuing Operations stood at -$41.8 million in 2020, then dropped by 20.33% to -$50.2 million in 2021, then dropped by 20.59% to -$60.6 million in 2022, then slumped by 49.01% to -$90.3 million in 2023, then increased by 0.79% to -$89.6 million in 2024.